IONS - IONIS PHARMACEUTICALS INC

79.45
0.790   0.994%

Share volume: 2,493,981
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$78.66
0.79
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 16%
Dept financing 47%
Liquidity 75%
Performance 48%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.06%
1 Month
-4.83%
3 Months
-2.73%
6 Months
29.76%
1 Year
135.41%
2 Year
79.79%
Key data
Stock price
$79.45
P/E Ratio 
0.00
DAY RANGE
$77.67 - $80.06
EPS 
-$2.38
52 WEEK RANGE
$23.95 - $86.74
52 WEEK CHANGE
$131.03
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-31-2025
BETA 
0.45
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,629,868
AVERAGE 30 VOLUME 
$2,227,206
Company detail
CEO: Brett P. Monia
Region: US
Website: ionispharma.com
Employees: 800
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.

Recent news